The genetics of multiple sclerosis: An up-to-date review

Immunological Reviews

Volumn 248, Issue 1, 2012, Pages 87-103

  Gourraud, Pierre Antoine ^a   Harbo, Hanne F ^a,b   Hauser, Stephen L ^a   Baranzini, Sergio E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Experimental autoimmune encephalitis; Major histocompatibility complex; Multiple sclerosis; Neuroimmunology

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ALLELE; ARTICLE; EPIGENETICS; EPISTASIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETICS; HERITABILITY; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL MARKERS; ENVIRONMENT; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; MULTIPLE SCLEROSIS;

EID: 84862747867     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2012.01134.x     Document Type: Article

References (130)

1. Hauser SL, Goodin DS. Multiple sclerosis and other demyelinating diseases. In: Longo DI ed. Harrison's Principles of Internal Medicine, 18th edn. New York: McGraw-Hill, 2012:3395-3409.
2. Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet 1972;1:1240-1241.
3. Naito S, Namerow N, Mickey MR, Terasaki PI. Multiple sclerosis: association with HL-A3. Tissue Antigens 1972;2:1-4.
4. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991;38:1-15.
5. Barcellos LF, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006;15:2813-2824.
6. Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-219.
7. Brynedal B, et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE 2007;2:e664.
8. Harbo HF, et al. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 2004;63:237-247.
9. Gusella JF, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983;306:234-238.
10. Ebers GC, et al. A full genome search in multiple sclerosis. Nat Genet 1996;13:472-476.
11. Haines JL, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet 1996;13:469-471.
12. Kuokkanen S, et al. A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2. Nat Genet 1996;13:477-480.
13. Sawcer S, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996;13:464-468.
14. Sawcer S, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005;77:454-467.
15. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-182.
16. Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet 2001;17:502-510.
17. Sawcer S. Bayes factors in complex genetics. Eur J Hum Genet 2010;18:746-750.
18. Hafler DA, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-862.
19. Gregory SG, et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007;39:1083-1091.
20. Lundmark F, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007;39:1108-1113.
21. ANZgene. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009;41:824-828.
22. Jakkula E, et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet 2010;86:285-291.
23. Sanna S, et al. Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nat Genet 2010;42:495-497.
24. Nischwitz S, et al. Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. J Neuroimmunol 2010;227:162-166.
25. Briggs FB, Shao X, Goldstein BA, Oksenberg JR, Barcellos LF, De Jager PL. Genome-wide association study of severity in multiple sclerosis. Genes Immun 2011;12:615-625.
26. De Jager PL, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009;41:776-782.
27. Baranzini SE, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009;18:767-778.
28. Comabella M, et al. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500, 000 single nucleotide polymorphisms. PLoS ONE 2008;3:e3490.
29. Burton PR, et al. Association scan of 14, 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-1337.
30. Maier LM, et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 2009;5:e1000322.
31. Baranzini SE. The genetics of autoimmune diseases: a networked perspective. Curr Opin Immunol 2009;21:596-605.
32. Cotsapas C, et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet 2011;7:e1002254.
33. Ramagopalan SV, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010;20:1352-1360.
34. Ramagopalan SV, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009;5:e1000369.
35. Ramagopalan SV, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011;70:881-886.
36. Baranzini SE, et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010;464:1351-1356.
37. Amiel JC. Study of the leukocyte phenotypes in Hodkin's disease. In: Curtoni ES, Mattiuz PL, Tosi RM eds. Histocompatibility Testing 1967 Report of a Conference and Workshop, Torino and Saint-Vincent, Italy, 14-24 June 1967. København: Munksgaard, 1967:458.
38. McDevitt HO, Chinitz A. Genetic control of the antibody response: relationship between immune response and histocompatibility (H-2) type. Science 1969;163:1207-1208.
39. Thorsby E. Invited anniversary review: HLA associated diseases. Hum Immunol 1997;53:1-11.
40. Jersild C, Fog T, Hansen GS, Thomsen M, Svejgaard A, Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973;2:1221-1225.
41. Bertrams HJ, Kuwert EK. Association of histocompatibility haplotype HLA-A3-B7 with multiple sclerosis. J Immunol 1976;117:1906-1912.
42. Compston DA, Batchelor JR, McDonald WI. B-lymphocyte alloantigens associated with multiple sclerosis. Lancet 1976;2:1261-1265.
43. Vartdal F, Sollid LM, Vandvik B, Markussen G, Thorsby E. Patients with multiple sclerosis carry DQB1 genes which encode shared polymorphic amino acid sequences. Hum Immunol 1989;25:103-110.
44. Spurkland A, Celius EG, Knutsen I, Beiske A, Thorsby E, Vartdal F. The HLA-DQ(alpha 1*0102, beta 1*0602) heterodimer may confer susceptibility to multiple sclerosis in the absence of the HLA-DR(alpha 1*01, beta 1*1501) heterodimer. Tissue Antigens 1997;50:15-22.
45. Caballero A, Alves-Leon S, Papais-Alvarenga R, Fernandez O, Navarro G, Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro- Brazilians. Tissue Antigens 1999;54:524-526.
46. Kaushansky N, Altmann DM, David CS, Lassmann H, Ben-Nun A. DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP). J Neuroinflammation 2012;9:29.
47. McElroy JP, et al. Refining the association of MHC with multiple sclerosis in African Americans. Hum Mol Genet 2010;19:3080-3088.
48. Oksenberg JR, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004;74:160-167.
49. Caillier SJ, et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol 2008;181:5473-5480.
50. Harbo HF, et al. Norwegian Sami differs significantly from other Norwegians according to their HLA profile. Tissue Antigens 2010;75:207-217.
51. Harbo HF, et al. Low frequency of the disease-associated DRB1*15-DQB1*06 haplotype may contribute to the low prevalence of multiple sclerosis in Sami. Tissue Antigens 2007;69:299-304.
52. Brassat D, et al. The HLA locus and multiple sclerosis in Sicily. Neurology 2005;64:361-363.
53. Coraddu F, et al. A genome screen for multiple sclerosis in Sardinian multiplex families. Eur J Hum Genet 2001;9:621-626.
54. Marrosu MG, et al. Sardinian multiple sclerosis is associated with HLA-DR4: a serologic and molecular analysis. Neurology 1988;38:1749-1753.
55. Marrosu MG, Murru MR, Costa G, Murru R, Muntoni F, Cucca F. DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. Hum Mol Genet 1998;7:1235-1237.
56. Marrosu MG, et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum Mol Genet 2001;10:2907-2916.
57. Muntoni F, et al. Different HLA DR2-DQw1 haplotypes in Sardinian and northern Italian populations: implications for multiple sclerosis susceptibility. Tissue Antigens 1991;38:34-36.
58. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000;55:140-148.
59. Rubio JP, et al. Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis. Am J Hum Genet 2002;70:1125-1137.
60. Yeo TW, et al. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol 2007;61:228-236.
61. Link J, et al. Two HLA class I genes independently associated with multiple sclerosis. J Neuroimmunol 2010;226:172-176.
62. Healy BC, et al. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology 2010;75:634-640.
63. Bergamaschi L, et al. Association of HLA class I markers with multiple sclerosis in the Italian and UK population: evidence of two independent protective effects. J Med Genet 2011;48:485-492.
64. Lorentzen AR, et al. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol 2009;65:658-666.
65. Cree BA, et al. A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01. PLoS ONE 2010;5:e11296.
66. Lincoln MR, et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci USA 2009;106:7542-7547.
67. Gregersen JW, et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 2006;443:574-577.
68. Hensiek AE, et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;72:184-187.
69. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000;48:211-219.
70. Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 2000;178:132-135.
71. Smestad C, et al. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007;14:835-840.
72. Romero-Pinel L, et al. HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population. Eur J Neurol 2011;18:337-342.
73. Imrell K, Greiner E, Hillert J, Masterman T. HLA-DRB115 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J Neuroimmunol 2009;210:128-130.
74. Cree BA, et al. Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol 2009;66:226-233.
75. Okuda DT, et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009;132:250-259.
76. Vandiedonck C, Giraud M, Garchon HJ. Genetics of autoimmune myasthenia gravis: the multifaceted contribution of the HLA complex. J Autoimmun 2005;25(Suppl.):6-11.
77. Gourraud PA. When is the absence of evidence, evidence of absence? Use of equivalence-based analyses in genetic epidemiology and a conclusion for the KIF1B rs10492972*C allelic association in multiple sclerosis. Genet Epidemiol 2011;35:568-571.
78. Zuvich RL, et al. Interrogating the complex role of chromosome 16p13.13 in multiple sclerosis susceptibility: independent genetic signals in the CIITA-CLEC16A-SOCS1 gene complex. Hum Mol Genet 2011;20:3517-3524.
79. Babron MC, et al. Determination of the real effect of genes identified in GWAS: the example of IL2RA in multiple sclerosis. Eur J Hum Genet 2012;20:321-325.
80. Kofler DM, Severson CA, Mousissian N, De Jager PL, Hafler DA. The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferation. J Immunol 2011;187:3286-3291.
81. Couturier N, et al. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 2011;134:693-703.
82. Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001;154:69-74.
83. Biran I, Steiner I. Smoking is a risk factor for multiple sclerosis. Neurology 2004;63:763.
84. Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 2003;61:1122-1124.
85. Hedstrom AK, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011;134:653-664.
86. Sawcer S, Hellenthal G. The major histocompatibility complex and multiple sclerosis: a smoking gun? Brain 2011;134:638-640.
87. Hawkes CH. Smoking is a risk factor for multiple sclerosis: a metanalysis. Multiple Sclerosis 2007;13:610-615.
88. Mkhikian H, et al. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun 2011;2:334.
89. Lee SU, et al. N-glycan processing deficiency promotes spontaneous inflammatory demyelination and neurodegeneration. J Biol Chem 2007;282:33725-33734.
90. Auffray C, Charron D, Hood L. Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med 2010;2:57.
91. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011;8:184-187.
92. Corvol JC, et al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci USA 2008;105:11839-11844.
93. McKinney EF, et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010;16:586-591.
94. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 2011;63:437-459.
95. Meyer MR, Maurer HH. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics 2011;12:215-233.
96. Baranzini SE, et al. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol 2005;3:e2.
97. Martinez-Rodriguez JE, et al. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin Immunol 2011;141:348-356.
98. Bielekova B, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103:5941-5946.
99. Bustamante MF, et al. Implication of the toll-like receptor 4 pathway in the response to interferon-beta in multiple sclerosis. Ann Neurol 2011;70:634-645.
100. Koike F, et al. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol 2003;139:109-118.
101. Wandinger KP, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001;50:349-357.
102. Wandinger KP, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003;361:2036-2043.
103. van Baarsen LG, et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 2008;3:e1927.
104. Sturzebecher S, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003;126:1419-1429.
105. Sellebjerg F, et al. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol 2009;16:1291-1298.
106. Sellebjerg F, et al. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Multiple Sclerosis 2008;14:615-621.
107. Muraro PA, et al. Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J Neuroimmunol 2004;150:123-131.
108. Killestein J, Polman CH. Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011;7:221-228.
109. Gilli F. Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta. J Interferon Cytokine Res 2010;30:733-741.
110. Bertolotto A, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psych 2004;75:1294-1299.
111. Bertolotto A, Gilli F. Interferon-beta responders and non-responders. A biological approach. Neurol Sci 2008;29(Suppl.):S216-S217.
112. Warner AW, et al. Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group. Clin Pharmacol Therapeut 2011;89:529-536.
113. Lyons PA, et al. Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification. BMC Genomics 2007;8:64.
114. Bejarano B, et al. Computational classifiers for predicting the short-term course of multiple sclerosis. BMC Neurol 2011;11:67.
115. Ioannidis JP. Prediction of cardiovascular disease outcomes and established cardiovascular risk factors by genome-wide association markers. Circ Cardiovasc Genet 2009;2:7-15.
116. Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009;181:488-493.
117. Foster KR. The sociobiology of molecular systems. Nat Rev Genet 2011;12:193-203.
118. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12:56-68.
119. Baranzini SE. Systems-based medicine approaches to understand and treat complex diseases. The example of multiple sclerosis. Autoimmunity 2006;39:651-662.
120. Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004;5:101-113.
121. Ideker T, Sharan R. Protein networks in disease. Genome Res 2008;18:644-652.
122. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. Proc Natl Acad Sci USA 2007;104:8685-8690.
123. Schadt EE, Friend SH, Shaywitz DA. A network view of disease and compound screening. Nat Rev Drug Discov 2009;8:286-295.
124. Sieberts SK, Schadt EE. Moving toward a system genetics view of disease. Mamm Genome 2007;18:389-401.
125. Gutierrez-Achury J, Coutinho de Almeida R, Wijmenga C. Shared genetics in coeliac disease and other immune-mediated diseases. J Int Med 2011;269:591-603.
126. Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009;10:43-55.
127. Wang L, Khankhanian P, Baranzini SE, Mousavi P. iCTNet: a Cytoscape plugin to produce and analyze integrative complex traits networks. BMC Bioinformatics 2011;12:380.
128. Patsopoulos NA, et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011;70:897-912.
129. Kwon OJ, et al. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol 1999;56:555-560.
130. Marrosu MG, et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am J Hum Genet 1997;61:454-457.